Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) presented a retrospective study at the SLEEP 2022 Annual Meeting, highlighting positive results from 786 patients using its proprietary oral appliances. The study found a 4.5% increase in transpalatal widths and an 11.1% increase in airway volume. Notably, 61.6% of the subset of patients showed a reduction of over 50% in the Apnea Hypopnea Index (AHI). Vivos' Complete Airway Repositioning and/or Expansion (CARE) therapy may represent a significant advancement for OSA treatment, offering a finite treatment duration of 12-24 months.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced two presentations at SLEEP 2022, an event hosted by the Associated Professional Sleep Societies in Charlotte, N.C., from June 4 to 8, 2022. Dr. Seth Heckman will present a retrospective study on non-surgical maxillary expansion on June 6, while Dr. J. Steven Alexander will discuss The Vivos Method's science on June 8. This participation underscores Vivos' commitment to advancing research in addressing dentofacial abnormalities and obstructive sleep apnea.
Vivos Therapeutics (VVOS) reported a revenue of $3.5 million for Q1 2022, a slight increase from $3.4 million in Q1 2021. Appliance revenue rose 19%, with 2,965 units sold. Gross profit decreased to $2.4 million, resulting in a gross margin of 68%. The company treated approximately 27,000 patients and trained over 1,500 dentists, marking significant growth. Vivos plans to open its third Pneusomnia Sleep Center in May 2022, aiming for more in the year. CEO R. Kirk Huntsman noted improvements starting in March, citing a 28% increase in appliance sales.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its financial results for Q1 2022 on May 16, 2022, after market close. A conference call will follow at 5:00 pm ET, where management will discuss results and strategic milestones. The company focuses on innovative solutions for dentofacial abnormalities and mild to moderate obstructive sleep apnea (OSA). The Vivos Method has effectively treated approximately 25,000 patients globally by trained dentists. A replay of the call will be available until May 30, 2022, along with a webcast accessible on Vivos' website.
Vivos Therapeutics, a medical technology company, announced the opening of its third Pneusomnia Sleep Center in Toluca Lake, California, in May 2022. This center aims to provide a comprehensive treatment approach for obstructive sleep apnea (OSA)
Vivos Therapeutics (NASDAQ: VVOS) reported a 33% increase in fourth quarter revenue, totaling $4.4 million, and a 29% increase for the full year, reaching $16.9 million. The growth was driven by increased appliance sales and new revenue sources. The total number of oral appliance arches sold rose to 2,707 in Q4 and 11,355 for the full year. Gross profit was $3.1 million in Q4, with a gross margin of 71%. Vivos also secured its mmRNA device's acceptance by Medicare and registered products with Health Canada. Management will hold a conference call today at 5:00 pm ET.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company, will release its fourth quarter and full year 2021 financial results today, March 31, 2022, following market close. The company will host a conference call at 5:00 PM ET to discuss the results and outline its growth strategy. Vivos specializes in innovative treatments for dentofacial abnormalities and obstructive sleep apnea, with its method having been effective for approximately 25,000 patients globally.
Vivos Therapeutics (NASDAQ: VVOS) has been recognized by Fast Company as the 9th most innovative medical device company in 2022. The company specializes in non-surgical and non-invasive treatments for dentofacial abnormalities and obstructive sleep apnea (OSA). Their proprietary technique, the Vivos Method, offers a 12-24 month treatment option that significantly improves airway conditions. Currently, over 25,000 patients have been treated using this method, addressing a market where over 1 billion people suffer from sleep apnea, many of whom remain undiagnosed.
Vivos Therapeutics has announced a rebranding of its proprietary treatment system to The Vivos Method, aimed at enhancing clarity and approachability for dentists and patients. This method combines customized oral appliances with multidisciplinary protocols to treat obstructive sleep apnea (OSA) in 12 to 24 months, offering a non-invasive alternative to traditional CPAP machines and surgeries. Vivos reports success with over 25,000 patients treated globally by more than 1,450 dentists. The updated website provides extensive information, including patient testimonials and partnership opportunities.
Vivos Therapeutics, a medical technology company focused on innovative treatment for dentofacial abnormalities and obstructive sleep apnea, announced CEO Kirk Huntsman's participation in upcoming conferences. Huntsman will present at the Q1 Virtual Investor Summit on March 8, 2022, at 4:15 PM ET and will engage in a fireside chat at the 34th Annual ROTH Conference on March 15, 2022, at 8:30 AM PT. Recordings of the presentations will be available on Vivos' website. The company aims to provide non-surgical, cost-effective solutions for sleep apnea, having treated about 25,000 patients worldwide.